Sugi Predict

Sugi Predict / Compounds / SCHEMBL7186879

SCHEMBL7186879

SCHEMBL7186879

Cc1cccc(C)c1C(=O)C(CP=O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ LMNA P02545 2/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ CYP2C19 P33261 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ GPR52 Q9Y2T5 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ TAAR1 Q96RJ0 1/20 0.36
▸ EPHX1 P07099 1/20 0.36
▸ ITGB3 P05106 1/20 0.36
▸ ITGB1 P05556 1/20 0.36
▸ ITGAV P06756 1/20 0.36
▸ ITGA5 P08648 1/20 0.36
▸ KCNQ2 O43526 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182855 0.90 KCNQ2 (0.43) L3MBTL1LMNAHSD17B10CYP2C9ITGB1
SCHEMBL7188486 0.88 SLC6A2 (0.38) L3MBTL1LMNAHSD17B10CYP2C19MEN1
SCHEMBL7181114 0.85 L3MBTL1 (0.41) L3MBTL1LMNAHSD17B10CYP2C19MEN1
SCHEMBL7183772 0.84 CYP1A2 (0.37) LMNAHSD17B10CYP2C19MEN1CYP1A2
SCHEMBL7180927 0.82 LMNA (0.38) L3MBTL1LMNAHSD17B10CYP2C19MEN1
SCHEMBL7180897 0.82 L3MBTL1 (0.39) L3MBTL1LMNAHSD17B10CYP2C19MEN1
SCHEMBL7177336 0.81 L3MBTL1 (0.38) L3MBTL1LMNAHSD17B10CYP2C19MEN1
SCHEMBL7182204 0.81 KCNQ2 (0.44) LMNAHSD17B10CYP2C19MEN1HPGD
SCHEMBL7189505 0.81 L3MBTL1 (0.40) L3MBTL1LMNAHSD17B10CYP2C19MEN1
SCHEMBL7189392 0.81 CA12 (0.47) LMNAMEN1HPGDKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 L3MBTL1 302/4885LMNA 3241/4885HSD17B10 56/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 L3MBTL1 126/4885LMNA 3247/4885HSD17B10 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.